Aflibercept, also known as brand name Eyelea, has been recently touted as a 2013 blockbuster drug. With sales of Aflibercept in the United States thought to have surpassed 1.3 billion dollars in the 2013 calendar year, the pharmaceutical community has been optimistically awaiting final year end data. Marketed by Regeneron in the U.S., Eyelea {Aflibercept}[…]
Aflibercept Touted as 2013 Blockbuster Drug
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: AfliberceptAMDEuropean Commissionintraocular pressure Jan 08, 2014
Aflibercept Approved for Colorectal Cancer Treatment
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approval News Tags: Afliberceptcolorectal cancerIrinotecan Aug 03, 2012
On August 3, 2012, the United States Food and Drug Administration (USFDA) approved ziv-aflibercept injection ( Zaltrap, made by Sanofi and Regeneron Pharmaceuticals, Inc.) for use in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following treatment with an[…]
Aflibercept Is Proving to be a Diverse and Effectual Product
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: AfliberceptAMDcolorectal cancer Mar 12, 2012
Clinical development of an exciting new recombinant fusion protein, Aflibercept, is underway. As an inhibitor of VEGF, or the vascular endothelial growth factor receptor, aflibercept is currently in a phase III trial for second line metastatic colorectal cancer. This trial for Aflibercept is being conducted by Sanofi-Aventis and Regeneron Pharmaceuticals. Additional trials currently in progress[…]
